'Microdosers' of LSD and Magic Mushrooms are Wiser and More Creative
Thomas Anderson, University of Toronto and Rotem Petranker, York University, Canada
We just ran the first ever pre-registered scientific study on the microdosing of psychedelics and found some very promising results.
We compared people who microdose — that is, who take a psychedelic substance such as LSD (lysergic acid diethylamide) or “magic” mushrooms (psilocybin) in very small quantities — with those who don’t, and found that microdosers had healthier scores on key mental health and well-being measures.
Subtle changes, not hallucinations
Psychedelics microdosing can mean taking five to 20 micrograms of LSD, 0.1 – 0.3 grams of dried psilocybin-containing mushrooms or very low doses of more exotic substances, like 1P-LSD, ALD-52 or 4-AcO-DMT.
No matter the substance, microdosing implies a dose so low that the individual experiences only subtle changes, not hallucinations. People are not “tripping” on a microdose; they just go about their regular day, whether that means studying at school, going to work or taking care of the kids at home.
There has been no published science on whether microdosing works, but despite this, microdosing for self-enhancement and mental health has hit the media.
For example, a 2016 article in Wired magazine described young professionals in San Francisco and Silicon Valley microdosing to enhance their creativity and focus, and to gain a competitive advantage.
Ayelet Waldman attributed her increased well-being to microdosing in A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage and My Life. More recently, Michael Pollan’s How to Change Your Mind has further attracted mainstream attention to psychedelics.
Higher wisdom and creativity
No experimental study has evaluated psychedelic microdosing, and neither did we.
Randomized placebo-controlled trials are needed to talk definitively about the effects of microdosing. In the meantime, we investigated the experiences of people who already microdose.
Our survey investigated the relationship between microdosing psychedelics and mental health. We recruited participants online, especially from Reddit’s microdosing community.
We asked our study participants about their microdosing patterns by having them fill in some questionnaires. As firm believers in Open Science, we have openly shared all our materials and you can find them here. Our findings are soon to be published in Pharmacology and you can access the preprint here.
We found that microdosers scored higher on “wisdom,” but wisdom is a tricky thing to define. In this context, “wisdom” implies considering multiple perspectives, learning from mistakes, being in tune with emotions and people and feeling a sense of connection. Using this definition, microdosers were more “wise.”
They were also more creative and open. If wisdom is tricky, creativity is even more so. In this case, creativity meant finding unusual uses for regular household objects: A brick and a knife. Microdosers came up with more useful, unusual and unique uses for these objects. This is a well-validated measure of divergent thinking, though certainly not the be-all and end-all of creativity.
Well, dysfunctional attitudes and negative emotionality (aka neuroticism) are bad. Dysfunctional attitudes are beliefs such as, “my value as a person depends greatly on what others think of me” or “if I ask a question, it makes me look inferior.” Neither of these are true, and they are unhealthy to believe as they imply vulnerability to stress and depression.
Microdosers endorsed less of these unhealthy beliefs. Likewise, high negative emotionality means a higher likelihood of having a mental health disorder, and microdosers had lower negative emotionality.
An exciting future for clinical science
Our results are promising. As promising as they seem, we don’t know whether microdosing actually caused any of these differences.
Maybe people with better mental health were more likely to experiment with microdosing, or perhaps there is some unknown cause that made people both more likely to microdose and to be creative.
At this point, we simply don’t know what caused the differences between the groups — just that these differences existed. We need to run controlled lab studies to actually find out.
Our preliminary work also shows that people report downsides to microdosing. For example, some people found microdosing increased anxiety and mood-instability; increased aches, pains and gastrointestinal distress were also relatively common.
The most common drawback was that microdosing is illegal. Did we forget to mention that? Yes, psychedelics are totally illegal!
LSD and psilocybin were made illegal in the 1971 UN Convention on Psychotropic Substances and remain so today. The exact laws differ depending on where you live, and using analogue substances can sometimes be a legal grey area but, for the most part, microdosing makes you a criminal.
What we need now are controlled lab experiments — randomized placebo-controlled trials of psychedelic microdosing to test safety and efficacy. Microdosing research, alongside full-dose psychedelics, promises an exciting future for clinical science and the study of human flourishing.
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Classically, the “amyloid” hypothesis, which ties the disease’s spread to that of amyloid protein, is thought to underlie AD’s pathology. After years of mixed to negative results in clinical trials, new research is underway to investigate what role the brain’s own immune system plays in amyloid-driven disease; an “infl-amyloid” hypothesis.
To pick apart the differences between individual cells in complex multicellular organisms, we need to look at cells one-by-one. This article takes a look at how several scientists in North America are using single cell proteomics (SCP) technologies to discern disease pathogenesis and enhance directed stem-cell differentiation.READ MORE